chronic neuroinflammation. 5 A key common pathological feature is the formation of a necrotic tissue core, which is unrecoverable, following stroke and TBI. [6] [7] [8] The onset and progression of secondary cell death of both diseases has been linked to the blood-brain barrier (BBB) breakdown, allowing various inflammatory cytokines to permeate the BBB, infiltrate the brain, and upregulate the inflammatory response, 9 altogether worsening the disease outcomes. In addition, several other exacerbating factors, such as oxidative stress, apoptosis, and mitochondrial dysfunction, have been shown to contribute to additional neurodegeneration following BBB damage. [10] [11] [12] [13] Hyperbaric oxygen therapy (HBOT) has been a treatment of interest for stroke as well as TBI over the past decade. 14, 15 HBOT utilizes a pressurized chamber, usually 2-3 absolute atmospheres (ATA), resulting in hyperoxygenation of tissues, inducing local angiogenesis in damaged regions of the body and recruitment of progenitor cells to the damaged regions. [16] [17] [18] The common, FDA-approved, uses of HBOT include treating patients with open wounds, often resulting from burn injuries or diabetic ulcers. 19, 20 The ability for a patient to undergo HBOT during the acute stage of stroke has been difficult to accomplish due to the overall timeline of the ischemic event and a limited number of facilities having the necessary equipment; therefore, the chronic stages of stroke have been targeted as a possible therapeutic window for HBOT. 14 This regimen seeks to ameliorate cognitive impairments synonymous with stroke, such as memory loss, language and comprehension deficits. 14, 21 Similarly, the unforeseen occurrence of TBI presents as a logistical hurdle in introducing HBOT as an acute treatment regimen for brain trauma patients. 22 Mechanistically, the secondary cell death with wider therapeutic window, characterized by inflammation has become the main target of HBOT treatment research, as reducing the levels of inflammatory cytokines has been linked to limiting peri-infarct/peri-impact tissue loss. 23, 24 However, the therapeutic mechanism of HBOT mediating the sequestration of inflammation is not fully understood. 25 A key unexplored research theme in the use of HBOT as a treatment for stroke and TBI involves investigations into the role of the preconditioning paradigm. Several studies have shown the preclinical efficacy of HBOT preconditioning for attenuating neuronal cell loss following an ischemic or traumatic event, but little mechanismbased assessment has elucidated the therapeutic pathways solicited by HBOT in these studies. [26] [27] [28] [29] The importance of alternative therapies for stroke and TBI patients has become evident. 30 To this end, cognizant that mitochondrial dysfunction closely approximates a pathologic inflammatory response resulting from ischemia and traumatic insult, evaluation of the mitochondria poses as a logical target of investigation in order to begin to understand the mechanism of HBOT preconditioning. [31] [32] [33] Of note, healthy extracellular mitochondria have been demonstrated to transfer from astrocytes into neurons following stroke resulting in reduced neuronal cell death. 34 In this study, we explored the ability of HBOT preconditioning to limit neuronal cell death following inflammatory insults, mimicking the secondary cell death associated with ischemic stroke and TBI.
More importantly, the potential role of HBOT in transferring mitochondria as a therapeutic mechanism in facilitating survival of the neuronal cells was also examined. 35 We hypothesized that a transfer of astrocytic mitochondria into neurons, following HBOT preconditioning, would improve neuronal cell viability following inflammatory insults.
| MATERIAL S AND ME THODS

| Cell culture
The research procedures involving animals were approved by the 
| HBOT
Hyperbaric oxygen therapy was administered using an OxyCure 3000 hyperbaric incubator (OxyHeal Health Group, National City, CA, USA). The HBOT regimen consisted of a single treatment at 2.5 absolute atmospheres lasting 90 minutes, with a 10-minute ascent and descent period ( Figure 2) . Following HBOT the cultures were returned to an incubator at 37°C and 5% CO 2 . Cultures remained in incubation for 24 hours prior to insult.
| Injury
To recreate the secondary cell death of inflammation observed in stroke and TBI, we employed two established inflammation-inducing agents. [36] [37] [38] The tumor necrosis factor-alpha (TNF-alpha, Fisher Scientific, 210TA020CF) only and HBOT plus TNF-alpha cocultures were treated with 50 ng/mL of TNF-alpha (RD) for 24 hours 39 in the incubator at 37°C and 5% CO 2 . The Lipopolysaccharide (LPS, Fisher Scientific, NC0202558) injury and HBOT plus LPS groups were treated with 100 ng/mL of LPS and returned to the incubator. 40 Each insult used the same medium as previously described for neurons and astrocytes. The control plates remained untreated.
| Measurement of cell viability
After the 24-hour incubation with TNF-alpha and LPS, all groups
were assessed for cell viability using calcein-AM (Fisher Scientific, 4892010K). After treatment, the astrocyte mesh inserts were removed and the remaining 6-well dish was incubated with 1 μmol/L calcein-AM for 30 minutes in the incubator at 37°C with 5% CO 2 .
Bright green fluorescence was retained within living cells. Five images were captured per well in randomly selected regions to determine cell viability at 10×. Analysis of cell intensity was performed by ImageJ (NIH). During cell counting, 30.25 cm 2 regions
were counted using ImageJ and calculated to determine the number of cells per 1 cm 2 . Analysis of data was conducted using GraphPad Prism 6 (GraphPad Software, La Jolla California USA).
| Immunocytochemistry
Prior to coculturing neurons and astrocytes, each was labeled with mitotracker, in order to visualize mitochondria belonging to each 
| Statistics
The data were evaluated using ANOVA followed by post hoc Bonferroni's tests. Statistical significance was preset at P < 0.05.
Data are presented as mean ± SE from quintuplicates of each treatment condition.
| RE SULTS
| Hyperbaric oxygen treatment rescues cell viability
Calcein-AM cell viability staining was performed and imaged using a fluorescent inverted microscope ( Figure 3 ). 
There was also a significant effect of HBOT on cell intensity for all six conditions (F 5,182 = 22.29, P < 0.001).
Post hoc comparisons using Bonferroni's tests indicated the mean number of cells per 1 cm 2 for the control group was not significantly different than the HBOT group. However, the TNF-alpha and LPS groups showed a significant reduction when compared to the control group (P < 0.001, P < 0.001). HBOT preconditioning prior to TNF-alpha insult resulted in a significant increase in cell bodies when compared to the TNF-alpha group (P < 0.001). Similarly, the F I G U R E 3 Primary cortical neuron cell viability. Administration of Hyperbaric oxygen therapy (HBOT) precondition occurred 24 h prior to injury onset. Primary rat neuronal cells (PRNCs) cocultured with astrocytes were subjected to HBOT for 90 min in the preconditioning group. After the insult was introduced to the PRNCs cocultured with astrocytes for 24 h, the cell viability was analyzed by Calcein-AM staining. Cell counting was performed and standardized per 1 cm 2 .
Intensity of signal was also calculated as described in the materials and methods. *P < 0.05, **P < 0.01, ***P < 0.001. The scale bar corresponds to 20 μm
HBOT + LPS group demonstrated a significant increase in viable cell
bodies versus the LPS group (P < 0.001).
Post hoc comparisons using Bonferroni's tests were also conducted for cell intensity. These results reiterated there was no significant difference in the means between the control group and the HBOT preconditioning group. Again, there was a significant reduction of intensity in the TNF-alpha and LPS groups when compared to the control group (P < 0.001, P < 0.001). When HBOT was administered prior to TNF-alpha it yielded a significantly increased intensity versus the TNF-alpha group (P < 0.001). Also, HBOT preconditioning prior to LPS administration also resulted in a significant increase in intensity versus the LPS group (P < 0.01).
| Hyperbaric oxygen therapy stimulates mitochondria transfer
Mitochondria transfer was imaged using a scanning laser confocal mi- 
| Live imaging following HBOT demonstrates mitochondrial transfer
Live imaging was conducted using a scanning laser confocal microscope to capture images at 5-minute intervals over a 30-minute period ( Figure 5 ). At acute period after HBOT initiation, live imaging revealed absence of Mitotracker-labeled mitochondria at 0 minute but its presence at 5 minutes ( Figure 5) . Similarly, at delayed period following HBOT initiation between 15 minutes and 20 minutes, migration of Mitotracker-labeled astrocytic mitochondria was visualized ( Figure 5 ).
F I G U R E 4
Mitochondrial transfer to primary cortical neurons. Migration of astrocyte mitochondria was tracked using Mitotracker staining of astrocytes prior to coculture with primary rat neuronal cells (PRNCs). Cocultures were subjected to the same preconditioning setting as previously described. Transfer of astrocyte mitochondria (cyan) was quantified by counting the number PRNCs containing cyan and dividing by the total number of PRNCs marked with MAP2 (red). DAPI was utilized to mark PRNC nuclei. *P < 0.05. **P < 0.01. The scale bar corresponds to 20 μm
| D ISCUSS I ON
The present study demonstrated the therapeutic effects of HBOT preconditioning in protecting against the secondary cell death associated with cerebrovascular events, specifically stroke, and TBI.
Primary neurons that were exposed to HBOT at 24 hours prior to an inflammatory insult exhibited a significant reduction in cell death Mitochondrial dysfunction stands as a therapeutic target in stroke and TBI due to its role in the secondary injury mechanism. 41, 42 However, HBOT as a treatment for cerebrovascular diseases has yielded mixed results. 14 The initiation of HBOT may dictate the therapeutic, or detrimental, outcomes. To date, the modality of HBOT preconditioning has been largely neglected;
HBOT's use as a prophylactic treatment for cerebrovascular diseases has only recently come into the spotlight for stroke and TBI research. Recent studies have postulated various mechanisms underlying HBOT's neuroprotective effects, including stabilizing the BBB and reducing inflammation. [43] [44] [45] [46] That BBB breakdown and inflammatory response are closely associated with mitochondrial impairment provided the impetus in the present study to examine the role of mitochondria as a therapeutic target of HBOT. 47, 48 Indeed, the transfer of mitochondria from astrocytes into neurons was observed after stroke. 34 Here, we showed that astrocytic mitochondria also transferred to neurons under ambient condition or when exposed to an inflammatory insult, but such transfer was more robustly recognized when treated with HBOT prophylactically. These findings form the basis for prophylactic HBOT for individuals who are at high risk of cerebrovascular events, specifically stroke and TBI, providing a method to reduce the Inflammation-plagued secondary cell death.
We found a substantial increase of astrocytic mitochondria in the primary neurons particularly in the HBOT-preconditioned groups via In the end, testing a variety of HBOT conditions in clinically relevant models are critical to achieving the optimal safe and effective regimen of mitochondria transfer-mediated neuroprotection. 52 Recent studies have established successful protocols for testing HBOT in rodent models for both single and multiple treatments. 53 Due to prior FDA-approved indications, HBOT has an established infrastructure in clinics allowing for it to be quickly implemented once treatments are optimized for humans. 19, 20 HBOT preconditioning poses as a prophylactic treatment for sequestration of inflammation, which is a pathological condition rampant in many cerebrovascular diseases. HBOT may be a leading alternative treatment for TBI and stroke modalities as steers away from invasive procedures such as exogenous cell transplantation following a major cerebrovascular event. 54 Mitochondrial transfer from astrocytes to neurons is a potential primary mechanism of action of HBOT to conferring neuroprotective effects against inflammation.
The ability to limit the severity of cerebrovascular injury in identified at-risk individuals may reduce the health burden and socioeconomic load of these diseases on our healthcare system and economy. 
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